ASCO 2015: Immunotherapy Shines
This article was originally published in Scrip
Three days into the 2015 American Society of Clinical Oncology annual meeting, there have been hundreds of data presentations, but a few have stuck out. The stand-outs come from across therapeutic categories and range from the hot area of immunotherapy to already-marketed products.
BMS changes the landscape
Bristol-Myers Squibb had a variety of data presentations at the conference, but its Checkmate-057 data caused quite a stir. The company's stock sold off when the late-breaking abstract was first released on 29 May due to the overall survival benefit only being seen in PD-L1 positive patients, but the full data presentation the following day has got analysts raving about the potential of Opdivo (nivolumab) in second-line non-small cell lung cancer (NSCLC).
The Phase III study of 582 previously-treated NSCLC patients showed that Opdivo was associated with a 27% reduction in the risk of progression or death compared with standard-of-care chemotherapy docetaxel. The drug compared with chemotherapy showed the best overall survival benefit – virtually double – in patients with greater than or equal to 10% PD-L1 expression (19.4 months vs 8.0 months).
Median Overall Survival Benefit by PD-L1 Expression
Level of Expression